For MZ SR:
Director General of the Pharmacy and Drug Section Policy MUDr. Adam Hlôška
Director of the Division of Classification, Pricing and Medicine PharmDr. Rastislav Pullmannn
Official of the Department of Classification, Pricing and Drug Administration policies of MVD. Erika Hanzely
For Boehringer Ingelheim:
Dr Hana Spitzer
JUDr. Marko Polakovič
Meeting at the request of the representative Boehringer Ingelheim, which on behalf of the company asked the Minister of Health of the Slovak Republic About the meeting on the availability of innovative oncology treatment in Slovakia, specifically medicine Vargatef.
From the point of view of substance, the meeting carried out at the Department of Pharmacy and Drug Policy.
The meeting was opened by SFLP MUDr. Adam Table
Boehringer Ingelheim:
By including Vargatef, the Ministry the health of the Slovak Republic (hereinafter referred to as "the Slovak Republic') It has been working for longer. Specific the application was dealt with twice by the Categorisation Commission; and then twice the rating board. The company considers that the decision of the Ministry was not sufficiently The reasons explained are therefore not clear to them decisions.
MZ SR:
The opinion of the pharmaco-economic group was negative and then the Categorisation Committee proceeded in terms of existing legislation. Categorisation Committee for Medicinal Products on 26.10.2015 recommends that MZ SR request from the holder Registration of an updated application, including an officially designated drug prices in other EU Member States; and Pharmacovigilance analysis including used pharmaco-economic model together with input data in electronic form. Subsequently, the company can call respond.
The sitting was closed by the Director General of the Department of Pharmacy Dr. Adam Hlôška
She wrote: Mr Erika Hanzely
He checked for Boehringer Ingelheim:Dr Hana
Spitzer
He approved: Dr Adam Hlôška
Date: 06.11.2015